Acrux Limited reports quarterly results: Should you buy?

Acrux Limited (ASX:ACR) posted some strong quarterly sales numbers this week, but it seems the market was expecting them.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Testosterone therapy manufacturer Acrux Limited (ASX: ACR) recently reported net sales of US$47.6 million for the final quarter of 2014 to take the full year total to US$170 million.

The full year sales are marginally down on 2013, although the final quarter's result of US$47.6 million is significantly up on the prior quarter and was the strongest quarter in 2014.

Volatile

It's been a topsy turvy year for Acrux shares as sales of its key Axiron product in the US market fluctuate heavily and investors continue to worry about regulatory risk.

Since May 2014 the stock has almost doubled in price only to fall in half again and then rise almost 50 per cent to sell for $1.45.

The regulatory risk carried by Acrux is the potential for the U.S. Food and Drug Administration (FDA) to issue an adverse finding against the safety of its testosterone therapy product.

Alternatively the FDA may require Axiron to carry even heavier health warnings (it already carries heavy health warnings), or it may change guidelines for medical professionals as to when to prescribe the product.

Short interest

Stocks that carry regulatory risk are a tempting target for short sellers with Acrux being one of the most heavily shorted stocks on the ASX, with nearly 10% of the equity on issue sold short as at 30 January, 2015.

The strong quarterly sales number seemingly not enough to squeeze the short holders out of their positions – presumably they are digging in to see how the regulatory risk plays out in the belief that Acrux is vulnerable as a largely one-trick pony.

It's a good trick though with strong underlying demand and good retention of market share for the easy-to-use testosterone therapy in the North American market. Acrux is also growing global sales of the product, with potential for that to develop over the medium term.

Indeed, much of the FDA's concern may be centred around the perception that sales of testosterone therapy are too strong, although how effective any attempt to apply stricter guidelines over prescriptions is remains to be seen.

Short sellers relying on a regulatory knock-out risk a large amount of egg on their face if any new regulatory requirements have little direct impact on prescription requirements, and sales continue to gather momentum.

Acrux is also a beneficiary of the falling Australian dollar, the potential for special dividends and a best-in-class product which appears to provide a slight competitive advantage in the testosterone therapy market. At $1.45, it remains a high-risk buy in my opinion.

Motley Fool contributor Tom Richardson owns shares in Acrux. You can find him on Twitter @tommyr345

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »